Casdin Reports 7.21M BLFS Shares, 15.0% Ownership in Schedule 13D/A

Rhea-AI Filing Summary

Casdin-related reporting persons disclosed beneficial ownership of 7,207,165 shares of BioLife Solutions, Inc. That stake represents 15.0% of the company based on 47,905,265 shares outstanding as of July 31, 2025. The filing names Casdin Capital, LLC; Casdin Partners Master Fund, L.P.; Casdin Partners GP, LLC; and Eli Casdin as the reporting persons.

The filing states the Fund used its working capital to purchase the shares and did not use borrowed funds except for ordinary working capital borrowing. The Reporting Persons say they currently have no plans to change board composition, management, capitalization or dividend policy but reserve the right to propose or effect such changes and to engage with management and other shareholders about maximizing shareholder value.

Positive

• Material stake disclosed: 7,207,165 shares representing 15.0% of outstanding common stock
• Transparent funding: purchases funded from the Fund's working capital with no borrowed funds except ordinary working capital borrowing
• Engagement intent: Reporting Persons state they have been and may continue to be in contact with management and other significant shareholders

Negative

• No current plans to effect changes: the Reporting Persons state they have no present plans to change the Board, management, capitalization, dividend policy, charter or bylaws
• Reserve rights to act: the Reporting Persons expressly reserve the right to effect or propose changes and to act in concert with others in the future
• Shared voting power only: reporting persons disclose no sole voting or dispositive power and instead have shared voting and dispositive power over the shares

Insights

Financial Analyst

TL;DR: A material 15.0% stake by Casdin is now disclosed, creating potential influence over shareholder outcomes.

The Schedule 13D/A shows a concentrated position: 7,207,165 shares (15.0%) of BLFS. For investors, a disclosed 13D typically signals an active investor with the ability to press for strategic changes or value-enhancing actions. The filing clarifies source of funds as the Fund's working capital and notes shared voting and dispositive power across the Casdin entities and Eli Casdin. No immediate corporate actions are proposed, but the position size is large enough to be market-moving or to affect takeover dynamics and shareholder negotiations.

Corporate Governance Expert

TL;DR: Casdin asserts no current plans to change governance yet reserves rights to engage and act with others.

The filing explicitly disclaims present intent to change the Board, management, charter, dividend policy, or capitalization, but it also reserves the right to pursue such actions later and to act in concert with other shareholders. The reporting persons hold shared voting and dispositive power over the 7.2M shares, which means influence will be exercised collectively through the Casdin entities. This posture is consistent with an investor seeking options while avoiding immediate escalation.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 4)

BioLife Solutions, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

09062W204

(CUSIP Number)

Casdin Capital, LLC
1350 Avenue Of The Americas, Suite 2405
New York, NY, 10019
(212) 897-5438

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

08/11/2025

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 09062W204

1

Name of reporting person

Casdin Capital, LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 7,207,165.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 7,207,165.00

11

Aggregate amount beneficially owned by each reporting person

7,207,165.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

15.0 %

14

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13D

CUSIP No. 09062W204

1

Name of reporting person

Casdin Partners Master Fund, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 7,207,165.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 7,207,165.00

11

Aggregate amount beneficially owned by each reporting person

7,207,165.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

15.0 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

CUSIP No. 09062W204

1

Name of reporting person

Casdin Partners GP, LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 7,207,165.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 7,207,165.00

11

Aggregate amount beneficially owned by each reporting person

7,207,165.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

15.0 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

CUSIP No. 09062W204

1

Name of reporting person

Eli Casdin

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 7,207,165.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 7,207,165.00

11

Aggregate amount beneficially owned by each reporting person

7,207,165.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

15.0 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, par value $0.001 per share
(b)	Name of Issuer: BioLife Solutions, Inc.
(c)	Address of Issuer's Principal Executive Offices: 3303 Monte Villa Parkway, Suite 310, Bothell, WASHINGTON , 98021.
Item 1 Comment: The name of the issuer is BioLife Solutions, Inc., a Delaware corporation (the "Issuer"). The address of the Issuer's principal executive offices is 3303 Monte Villa Parkway, Suite 310, Bothell, Washington, 98021. This Schedule 13D amendment relates to the Issuer's Common Stock, par value $0.001 per share (the "Shares").
Item 2.	Identity and Background
(a)	(a), (f) This Schedule 13D is being filed jointly by Casdin Capital, LLC, a Delaware limited liability company ("Casdin"), Casdin Partners Master Fund, L.P., a Cayman Islands exempted limited partnership (the "Fund"), Casdin Partners GP, LLC, a Delaware limited liability company (the "GP") and Eli Casdin, a United States citizen (collectively, the "Reporting Persons").
(b)	The principal business address for each of the Reporting Persons is 1350 Avenue of the Americas, Suite 2600, New York, New York 10019.
(c)	Eli Casdin is the managing member of Casdin and the GP. The principal business of Casdin is serving as an investment adviser to its clients. The principal business of the GP is serving as the general partner to certain private funds. Casdin is the investment manager to the Fund and the GP is the general partner of the Fund. The principal business of the Fund is purchasing, holding and selling securities for investment purposes.
(d)	(d), (e) During the last five years, none of the Reporting Persons has been (a) convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (b) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. The Reporting Persons disclaim membership in a group.
Item 3.	Source and Amount of Funds or Other Consideration
	The funds for the purchase of the Shares by the Fund came from the working capital of the Fund, over which the Reporting Persons, through their roles described above in Item 2(c), exercise investment discretion. No borrowed funds were used to purchase the Shares, other than borrowed funds used for working capital purposes in the ordinary course of business.
Item 4.	Purpose of Transaction
	The Reporting Persons have acquired their Shares of the Issuer for investment. The Reporting Persons have no plans or proposals as of the date of this filing which, other than as expressly set forth below, would relate to or would result in: (a) any extraordinary corporate transaction involving the Issuer; (b) any change in the present Board of Directors or management of the Issuer; (c) any material change in the present capitalization or dividend policy of the Issuer; (d) any material change in the operating policies or corporate structure of the Issuer; (e) any change in the Issuer's charter or by-laws; (f) the Shares of the Issuer ceasing to be listed from a national securities exchange or to ceasing to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; or (g) causing the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934. The Reporting Persons, however, reserve the right, at a later date, to effect one or more of such changes and may dispose of or enter into other transactions in the shares they may be deemed to beneficially own. The Reporting Persons have been and may continue to be in contact with members of the Issuer's management, the Issuer's Board of Directors, other significant shareholders and others regarding alternatives that the Issuer could employ to maximize shareholder value. The Reporting Persons further reserve the right to act in concert with any other shareholders of the Issuer, or other persons, for a common purpose should it determine to do so, and/or to recommend courses of action to management and the shareholders of the Issuer.
Item 5.	Interest in Securities of the Issuer
(a)	As of the date hereof, Casdin, the Fund, the GP and Eli Casdin may be deemed to be the beneficial owners of 7,207,165 Shares, constituting 15.0% of the Shares based upon 47,905,265* Shares outstanding. Casdin has the sole power to vote or direct the vote of 0 Shares; has the shared power to vote or direct the vote of 7,207,165 Shares; has the sole power to dispose or direct the disposition of 0 Shares; and has the shared power to dispose or direct the disposition of 7,207,165 Shares. The Fund has the sole power to vote or direct the vote of 0 Shares; has the shared power to vote or direct the vote of 7,207,165 Shares; has the sole power to dispose or direct the disposition of 0 Shares; and has the shared power to dispose or direct the disposition of 7,207,165 Shares. The GP has the sole power to vote or direct the vote of 0 Shares; has the shared power to vote or direct the vote of 7,207,165 Shares; has the sole power to dispose or direct the disposition of 0 Shares; and has the shared power to dispose or direct the disposition of 7,207,165 Shares. Eli Casdin has the sole power to vote or direct the vote of 0 Shares; has the shared power to vote or direct the vote of 7,207,165 Shares; has the sole power to dispose or direct the disposition of 0 Shares; and has the shared power to dispose or direct the disposition of 7,207,165 Shares. The transactions by the Reporting Persons in the Shares are set forth in Exhibit B. *This outstanding Shares figure reflects the number of outstanding Shares as of July 31, 2025.
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	Not Applicable.
Item 7.	Material to be Filed as Exhibits.
	Exhibit A: Joint Filing Agreement Exhibit B: Schedule of Transactions in Shares

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Casdin Capital, LLC

Signature:	By Eli Casdin
Name/Title:	Eli Casdin / Managing Member
Date:	08/13/2025

Casdin Partners Master Fund, L.P.

Signature:	By Eli Casdin
Name/Title:	Eli Casdin / Managing Member of its General Partner
Date:	08/13/2025

Casdin Partners GP, LLC

Signature:	By Eli Casdin
Name/Title:	Eli Casdin / Managing Member
Date:	08/13/2025

Eli Casdin

Signature:	By Eli Casdin
Name/Title:	Eli Casdin
Date:	08/13/2025

Comments accompanying signature:

* This reporting person disclaims beneficial ownership of these reported securities except to the extent of its pecuniary interest therein, and this report shall not be deemed an admission that any such person is the beneficial owner of these securities for purposes of Section 16 of the U.S. Securities Exchange Act of 1934, as amended, or for any other purpose. Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

FAQ

What stake did Casdin report in BioLife Solutions (BLFS)?

The filing reports beneficial ownership of 7,207,165 shares, representing 15.0% of BLFS based on 47,905,265 shares outstanding as of July 31, 2025.

Who filed the Schedule 13D/A for BLFS?

The Schedule 13D/A was filed jointly by Casdin Capital, LLC, Casdin Partners Master Fund, L.P., Casdin Partners GP, LLC and Eli Casdin.

When was the event requiring this Schedule 13D filed?

The date of the event requiring filing is stated as 08/11/2025, and signatures on the amendment are dated 08/13/2025.

How were the shares purchased?

The filing states the Fund purchased the shares using the Fund's working capital and did not use borrowed funds other than ordinary working capital borrowing.

Does Casdin plan to change BioLife's management or governance?

The Reporting Persons state they currently have no plans to change the Board, management, capitalization, dividend policy, charter, or bylaws but reserve the right to effect such changes in the future.